Researchers in Spain, who noted that diabetes is common in patients with pneumonia, examined whether the clinical features and outcomes of pneumonia were altered by the presence of diabetes. The results of their study showed that patients with diabetes had more serious pneumonia and more hospital stays, compared with patients without diabetes.
The researchers further reported that diabetes was independently associated with a higher risk of death from pneumonia. The patients with diabetes who died of pneumonia had more underlying diseases and diabetes-related problems. The microorganisms responsible for the pneumonia, however, were the same in both the patients with diabetes and the control group, according to the report in Chest (November 2005).
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs